An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
NCT ID: NCT00206648
Last Updated: 2014-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
271 participants
INTERVENTIONAL
2003-03-31
2005-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1
Betaferon/Betaseron
Betaseron 250 µg SC every other day
Arm 2
Betaferon/Betaseron
Avonex 30 µg IM once per week
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Betaferon/Betaseron
Betaseron 250 µg SC every other day
Betaferon/Betaseron
Avonex 30 µg IM once per week
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bayer Study Director
Role: STUDY_DIRECTOR
Bayer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tucson, Arizona, United States
Berkeley, California, United States
Irvine, California, United States
Loma Linda, California, United States
Los Angeles, California, United States
Sacramento, California, United States
San Jose, California, United States
Walnut Creek, California, United States
Walnut Creek, California, United States
Wilmington, Delaware, United States
Melbourne, Florida, United States
Miami, Florida, United States
Tampa, Florida, United States
Tampa, Florida, United States
Atlanta, Georgia, United States
Augusta, Georgia, United States
Columbus, Georgia, United States
Savannah, Georgia, United States
Flossmoor, Illinois, United States
Springfield, Illinois, United States
Fort Wayne, Indiana, United States
Indianapolis, Indiana, United States
Des Moines, Iowa, United States
Kansas City, Kansas, United States
Shreveport, Louisiana, United States
Baltimore, Maryland, United States
Detroit, Michigan, United States
Golden Valley, Minnesota, United States
Minneapolis, Minnesota, United States
Rochester, Minnesota, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
Reno, Nevada, United States
Albuquerque, New Mexico, United States
Albany, New York, United States
Buffalo, New York, United States
Mineola, New York, United States
New York, New York, United States
Asheville, North Carolina, United States
Winston-Salem, North Carolina, United States
Dayton, Ohio, United States
Oklahoma City, Oklahoma, United States
Medford, Oregon, United States
Philadelphia, Pennsylvania, United States
Providence, Rhode Island, United States
Charleston, South Carolina, United States
Houston, Texas, United States
Fairfax, Virginia, United States
Roanoke, Virginia, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Nepean, Ontario, Canada
Ottawa, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
307245
Identifier Type: -
Identifier Source: secondary_id
91293
Identifier Type: -
Identifier Source: org_study_id